
Heineken ® to Boost Bar Incomes by Turning Them into Film Sets
A Media Snippet accompanying this announcement is available by clicking on this link.
AMSTERDAM, April 10, 2025 (GLOBE NEWSWIRE) -- HEINEKEN is strengthening its commitment to the bar industry with the launch of 'Starring Bars' - a new initiative as part of its wider 'Back the Bars' platform. The programme will prioritise bars that serve Heineken® beer as filming locations, redirecting commercial production budgets into these businesses. To anchor this effort, Heineken® will be creating a global catalogue of these bars as film-ready locations.
As part of the project, Heineken® is also inviting movie directors, location scouts and other film industry professionals to consider these bars first when looking for a set. By highlighting these character-rich spaces, the initiative could put bars at the heart of Hollywood storytelling – as authentic settings, while ensuring the bars benefit financially from being featured in film and television productions.
Finding the right venues for film, TV, or advertising productions isn't easy, but it's even harder to keep a bar afloat. To tackle both challenges in one; Heineken® created 'Starring Bars', providing production teams with easier access to real bars they can book for shoots through a growing online catalogue available at www.starringbars.com. The site includes photos, floor plans, and availability, streamlining the scouting process. By choosing a real bar over a studio set, filmmakers bring added authenticity to on-screen storytelling, while supporting local businesses and communities.
To bring the 'Starring Bars' initiative to life, Heineken® is rolling out a dynamic visual campaign that puts bar owners in the spotlight and tells the stories of the people behind these venues. Heineken® is also sending moving billboards on a tour of major entertainment hubs to call on filmmakers to explore the catalogue and consider bars as prime shoot locations, with playful messages like 'Hey Director, these bars can handle a drama.'
Nabil Nasser, Global Head of Heineken® Brand, says, 'Bars are more than just places to grab a drink; they are community hubs and cultural landmarks. With 'Starring Bars,' we're spotlighting these venues and helping open new commercial opportunities to support them. This initiative is about backing the bar industry in a meaningful way, and we're inviting the entertainment world to be a part of that.'
Each year, Heineken® makes a lot of ads and fees for location rentals are a key piece of any ad production budget. Through 'Starring Bars,' that investment will now directly benefit bars – supporting owners and the communities they serve. Heineken® aims to build a comprehensive global catalogue of real bars that double as filming locations.
Heineken® is all about bringing people together and celebrating the connections that make bars special. 'Starring Bars' reflects this commitment, offering bar owners increased visibility, more foot traffic, and the chance to be featured in film and media.
About HEINEKEN:
HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken ® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brewing a Better World", sustainability is embedded in the business.
HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We employ over 85,000 employees and operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY).
Most recent information is available on HEINEKEN's website: www.theHEINEKENcompany.com and follow us on Twitter via @HEINEKENCorp.
PRESS CONTACT:
Sebastien-Nicolas Chiffrin
Edelman
sebastien-nicolas.chiffrin@edelman.com
+44 7580 979333
Photos accompanying this announcement are available at:

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
8 hours ago
- CTV News
Heineken to invest over US$2.7B in Mexico through 2028
MEXICO CITY — Beer maker Heineken will invest US$2.75 billion in different projects in Mexico, the company's CEO in the country said on Wednesday. Oriol Bonaclocha said during Mexican President Claudia Sheinbaum's morning press conference that the investment will include the construction of a new factory in the country's southeast. The new plant in the state of Yucatan will have an initial production capacity of 4 million hectoliters and that amount is expected to be doubled in the future depending on the company's needs, Bonaclocha said. 'We do not plan to close any factories, this is an expansion,' he added. In April, Grupo Modelo, the producer of Corona and other Mexican beer brands, announced it would invest more than $3.6 billion in Mexico, despite concerns over water shortages in the country. The relationship between beer makers and other industries like agriculture has been a longstanding issue in Mexico. Almost three years ago, the construction of a Constellation Brands brewery in Mexicali was halted to protect local water resources and moved to Veracruz in eastern Mexico. (Reporting by Raul Cortes and Aida Pelaez-Fernandez. Editing by Chizu Nomiyama and Mark Potter)


Cision Canada
9 hours ago
- Cision Canada
Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
TORONTO, June 11, 2025 /CNW/ - Specific Biologics Inc., a biotechnology company advancing Dualase® genome editors for precise and programmable in vivo genome editing, today announced the appointment of Paul J. Hastings as Chair of its Board of Directors. Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board Member of engineered cell therapy company Nkarta since 2018. He is also a current Director of EnGene, a non-viral gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate strategy as Chair of Pacira Biosciences, Proteon Therapeutics and Proteolix, and as a Director of ViaCyte, Relypsa and ViaCell, and previously held leadership roles in global biotechnology companies as President of Genzyme Therapeutics Europe and Genzyme Global Therapeutics, as well as progressive executive roles at Hoffmann-La Roche. A committed mentor and patient advocate, he co-founded and chairs the board of Youth Rally Inc. and serves on the Board of the Termeer Foundation. "I am thrilled to welcome Paul to the Board," said Brent Stead, CEO of Specific Biologics. "His proven ability to lead and scale high-impact biotechnology companies with breakthrough technologies will be instrumental as we advance our Dualase® platform toward the clinic for patients in need. We are entering an exciting new phase of growth, and Paul's leadership of the Board will be invaluable." "I'm honored to join the Board of Specific Biologics at such a pivotal time," said Hastings. "The Dualase® technology has the potential to reshape how we approach treating some of the most challenging genetic diseases. I look forward to working with the leadership team and Board to support Specific's mission and drive meaningful impact for patients with limited therapeutic options." Specific Biologics also extends its sincere gratitude to Dr. Steven Kanner for his dedicated service on the Board and guidance during a critical phase of the company's development. "Steve played a key role in helping shape our early strategy and set the foundation for our current momentum," said Stead. About Specific Biologics Inc. Specific Biologics is a venture-backed biotechnology company developing Dualase®, an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic repeat expansions in neurodegenerative disease. Its unique two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal models at diverse targets and indications.


Cision Canada
12 hours ago
- Cision Canada
ASUS Announces Key Milestone with Nebius and Showcases NVIDIA GB300 NVL72 System at GTC Paris 2025
Accelerating AI with scalable performance and next-gen infrastructure PARIS, June 11, 2025 /CNW/ -- ASUS today joined GTC Paris at VivaTech 2025 as a Gold Sponsor, highlighting its latest portfolio of AI infrastructure solutions and reinforcing its commitment to advancing the AI Factory vision with a full range of NVIDIA ® Blackwell Ultra solutions, delivering breakthrough performance from large-scale datacenter to personal desktop. ASUS is also excited to announce a transformative partnership milestone in its partnership with Nebius. Together, the two companies are enabling a new era of AI innovation built on NVIDIA's advanced platforms. Building on the success of the NVIDIA GB200 NVL72 platform deployment, ASUS and Nebius are now moving forward with strategic collaborations featuring the next-generation NVIDIA GB300 NVL72 platform. This ongoing initiative underscores ASUS's role as a key enabler in AI infrastructure, committed to delivering scalable, high-performance solutions that help enterprises accelerate AI adoption and innovation. Andrey Korolenko, Chief Product and Infrastructure Officer at Nebius said: "We have collaborated with ASUS for many years and appreciate its impressive capability to deliver swift and efficient solutions. ASUS not only delivers consistently against our exacting technical requirements, but also demonstrates deep professional expertise in building AI infrastructure. The company's forward-thinking approach and technical excellence have been a key enabler for our projects, and we look forward to working together to deliver the next generations of AI infrastructure." AI servers: Building NVIDIA AI Factories for enterprise Leading the charge in AI advancement, ASUS is driving scalable, agentic AI through increased token generation. At GTC Paris, ASUS will unveil its latest AI Factory infrastructure solutions built on NVIDIA RTX PRO Servers as well as the NVIDIA Grace Blackwell Ultra systems. The ASUS AI POD, built with the NVIDIA GB300 NVL72 system, delivers exceptional performance for complex AI inference tasks, making it ideal for advanced AI applications. Meanwhile, ASUS XA NB3I-E12, featuring the NVIDIA HGX B300 system, pushes the boundaries of AI computing with higher FLOPS and a massive 2.3TB of HBM3e memory — accelerating training and inference for large-scale models. To further address the growing demands of high-performance AI and HPC environments, ASUS introduced the new ESC8000A-E13P. This 4U NVIDIA MGX server supports up to eight NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs, NVIDIA BlueField-3 DPUs, and NVIDIA ConnectX-8 SuperNICs with built-in PCIe® 6.0 switches, offering seamless integration, performance optimization, and scalability for modern data centers and agile IT deployments AI Inferencing: Enabling intelligent services at scale ASUS also unveiled powerful AI inference solutions, introducing a new lineup of workstations and a compact-sized supercomputer engineered to tackle today's most demanding workloads. Leading the range is the ExpertCenter Pro ET900N G3, the first system powered by the NVIDIA GB300 Grace Blackwell Ultra Superchip, with up to 784GB of large coherent memory. Another is the groundbreaking ASUS Ascent GX10, a compact AI supercomputer powered by the NVIDIA GB10 Grace Blackwell Superchip, that delivers 1,000 AI TOPS performance for demanding workloads. Equipped with a NVIDIA Blackwell GPU, 20-core Arm CPU, and 128GB of memory, it supports AI models up to 200-billion parameters, placing petaflop-scale inferencing capabilities on developers' desks. Designed from the ground up for AI, both products deliver exceptional performance for large-scale training and inference on a desktop. Combined with the NVIDIA AI s oftware s tack, it is purpose-built for teams that demand the best in AI development. ASUS: Proven expertise in AI infrastructure With server expertise dating back to 1995, ASUS delivers reliable, end-to-end infrastructure solutions —ranging from individual components to fully integrated systems — backed by world-class R&D and global manufacturing capabilities. Driven by the Ubiquitous AI, Incredible Possibilities vision, ASUS supports clients in accelerating their advancement in the global AI race. Through flexible customization, deep technical expertise, and a proven track record in deployment, ASUS empowers enterprises to scale AI initiatives with confidence and efficiency.